ANICCA-Class II : A phase II Trial of nivolumab in strong class II expressing microsatellite stable colorectal cancer patients (MSS CRC)

Project Details

Short titleANICCA-Class II : A phase II Trial of nivolumab in strong class II expressing microsatellite stable colorectal cancer patients (MSS CRC)
StatusActive
Effective start/end date1/01/18 → 31/12/25

Funding

  • BRISTOL MYERS SQUIBB PHARMACEUTICALS